5 Biotech Stocks That Generated 1,000%+ Returns In 2020
5 Biotech Stocks That Generated 1,000%+ Returns In 2020
The biopharma sector weathered the COVID-19 pandemic fairly well, with the Shares Nasdaq Biotechnology Etf (NASDAQ:IBB) outperforming the S&P 500 Index. This defensive sector also benefited from opportunity in the form of SARS-CoV-2, the virus that causes COVID-19.
生物制药板块相当好地经受住了新冠肺炎疫情，纳斯达克生物技术交易所交易基金(纳斯达克股票代码：IBB)的表现优于标准普尔500指数。这一防御性部门还受益于导致新冠肺炎的SARS-CoV-2病毒带来的机遇。
It, therefore, comes as a no surprise that two of the top five gainers among biotech stocks are vaccine developers.
因此，生物技术类股中涨幅最大的五家公司中有两家是疫苗开发商，这一点也就不足为奇了。
Here are the biotechs that advanced in excess of 1,000% thus far this year:
以下是今年到目前为止进步超过1000%的生物技术：
Novavax, Inc. (NASDAQ:NVAX) (Gain: +2799%)
诺瓦克斯公司(纳斯达克市场代码：NVAX)(涨幅：+2799%)
Much of Novavax's rally is attributable to its coronavirus vaccine program. The company identified its investigational vaccine, codenamed NVX-CoV2373, in early April. It is a stable, prefusion protein made using the company's proprietary nanoparticle technology, with Matrix-M adjuvant added to it.
Novavax的反弹在很大程度上要归功于其冠状病毒疫苗计划。该公司在4月初确定了代号为NVX-CoV2373的研究疫苗。这是一种稳定的预融合蛋白，使用该公司的专利纳米颗粒技术，并添加了Matrix-M佐剂。
Ahead of the initiation of the coronavirus vaccine program, the shares received a lift from positive developments concerning its influenza vaccine candidate NanoFlu.
在冠状病毒疫苗计划启动之前，其流感疫苗候选NanoFlu的积极进展提振了股价。
After proceeding seamlessly with its vaccine program, Novavax Is currently facing a setback as it is experiencing a delay in the start of the U.S. leg of the late-stage study of NVX-CoV2373.
在无缝推进疫苗计划后，Novavax目前正面临挫折，因为它正经历着NVX-CoV2373晚期研究在美国的启动延迟。
With two companies having already received conditional approvals for their vaccine candidates, Novavax is under pressure to expeditiously bring its coronavirus vaccine program to fruition.
由于已经有两家公司获得了对其候选疫苗的有条件批准，Novavax面临着迅速实现其冠状病毒疫苗计划的压力。
Vaxart Inc (NASDAQ:VXRT) (+1940%)
Vaxart Inc(纳斯达克市场代码：VXRT)(+1940%)
This South San Francisco, California-based company was among the earliest to embark on a vaccine program against SARS-CoV-2.
这家总部位于加利福尼亚州旧金山南部的公司是最早开始对抗SARS-CoV-2疫苗计划的公司之一。
The company announced in late January the initiation of the program based on its proprietary oral vaccine platform, VAAST. The company selected a lead candidate, an oral recombinant vaccine, in late May.
该公司于1月底宣布启动该计划，该计划基于其专有口服疫苗平台VAAST。该公司在5月下旬选择了一种领先的候选疫苗，一种口服重组疫苗。
In a bid to expedite its vaccine program, Vaxart appointed Andrei Floroiu, a biopharma industry veteran with experience in vaccine manufacturing, as its CEO in mid-June. The company filed an investigational new drug application for commencing the Phase 1 study in early August, and the application was cleared by the FDA in mid-September. About a month later, the company commenced the Phase 1 study of the investigational vaccine, codenamed VXA-CoV2-1.
为了加快疫苗计划，Vaxart在6月中旬任命具有疫苗制造经验的生物制药行业资深人士Andrei Floroiu为首席执行官。该公司于8月初提交了一份开始第一阶段研究的调查性新药申请，并于9月中旬获得FDA的批准。大约一个月后，该公司开始了代号为VXA-CoV2-1的研究性疫苗的第一阶段研究。
"We look for interim follow-up safety updates at one month and two months post-dosing to be positive catalysts in 1Q21," HC Wainwright analyst Vernon Bernardino said in a note.
HC Wainwright分析师弗农·贝纳迪诺(Vernon Bernardino)在一份报告中表示：“我们希望在服药后一个月和两个月进行临时安全更新，以期在2011年第一季度起到积极的催化作用。”
相关链接：Sarepta，Amicus Top Biotech在关键二元事件之前选择：分析师
Cardiff Oncology Inc (NASDAQ:CRDF) (+1,563%)
加的夫肿瘤公司(纳斯达克市场代码：CRDF)(+1563%)
Cardiff's shares had been flatlining since late-2018 up until the middle of 2020.
卡迪夫的股价自2018年末以来一直持平，直到2020年年中。
The company's lead clinical-stage candidate, onvansertib is a third-generation, oral and highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine polo-like-kinase 1, which is over-expressed in multiple cancers including leukemias, lymphomas and solid tumors. It is being evaluated in multiple Phase 2 studies for indications, including metastatic castration-resistant prostate cancer, colorectal cancer and acute myeloid leukemia.
该公司临床阶段的主要候选药物onvansertib是一种第三代口服高度选择性的三磷酸腺苷竞争性丝氨酸/苏氨酸类Polo-like激酶1抑制剂，它在包括白血病、淋巴瘤和实体瘤在内的多种癌症中过度表达。它正在多个2期研究中进行适应症评估，包括转移性去势抵抗前列腺癌、结直肠癌和急性髓系白血病。
The shares began turning the corner after the company reported a $13.5 million equity investment in mid-June. It got another leg-up in mid-September following a presentation at the ESMO virtual conference, providing data on onvansertib in KRAS-mutant metastatic colorectal cancer. The rally has accelerated since then.
在该公司6月中旬公布了1350万美元的股权投资后，该公司股价开始好转。9月中旬，在ESMO虚拟会议上发表演讲后，它获得了另一项支持，提供了有关onvansertib在KRAS突变的转移性结直肠癌中的数据。此后涨势加速。
Genprex Inc (NASDAQ:GNPX) (+1,297%)
Genprex Inc(纳斯达克市场代码：GNPX)(+1297%)
This gene therapy company received a shot in the arm from a mid-February licensing agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes. The stock, however, gave back much of the gain in about a month.
这家基因治疗公司从2月中旬与匹兹堡大学签署的一项糖尿病基因疗法许可协议中获得了一剂强心针，这种基因疗法可能有可能治愈1型和2型糖尿病。然而，该股在大约一个月的时间里回吐了大部分涨幅。
The company's immunogene therapy Reqorsa is being evaluated for non-small cell lung cancer.
该公司的免疫基因疗法Reqorsa正在接受非小细胞肺癌的评估。
Trillium Therapeutics Inc (NASDAQ:TRIL) (+1,068%)
延龄治疗公司(纳斯达克市场代码：TRIL)(+1068%)
The clinical stage immuno-oncology company has been broadly higher this year, although its shares have pulled back since early December.
这家临床期免疫肿瘤学公司今年普遍走高，尽管其股价自12月初以来有所回落。
The company is developing two pipeline assets: TTI-621 and TTI-622. TTI-621 is currently being evaluated in a phase 1 trial in patients with relapsed/refractory hematologic malignancies, while TTI-622 is being studied in a two-part, phase 1a/1b study in patients with advanced relapsed or refractory lymphoma or multiple myeloma.
该公司正在开发两个管道资产：TTI-621和TTI-622。TTI-621目前正在复发/难治性血液恶性肿瘤患者的1期试验中进行评估，而TTI-622正在晚期复发或难治性淋巴瘤或多发性骨髓瘤患者中进行两部分1a/1b期研究。
Photo by Owen Beard on Unsplash.
欧文·比尔德在Unspash上的照片。
译文内容由第三方软件翻译。